25ᵗʰ European Hematology Association (EHA) Annual Congress - X4 Pharmaceuticals

25ᵗʰ European Hematology Association (EHA) Annual Congress

25ᵗʰ European Hematology Association (EHA) Annual Congress

June 2020

Oral CXCR4 Antagonist Mavorixafor Treatment in WHIM Syndrome: Results of an Open Label Phase 2 Study With Long-Term extension

© Copyright 2024 X4 Pharmaceuticals. All Rights Reserved. Terms of Use | Privacy | Compliance and Ethics